Clinical Trial: Kanglaite Injection Phase I Study

This study is no longer recruiting patients.

Sponsored by: Kanglaite-USA
Information provided by: Kanglaite-USA


The Kanglaite Injection (KLT)is a novel broad spectrum anti-cancer injection produced from traditional Chinese medicinal herbs (the Coix Seed). It was approved in China in 1995 and has become the most popular anti-cancer drug in China. In June of 2001, the Phase I study of KLT commenced at the Huntsman Cancer Institute in Salt Lake City, Utah, with the objectives of 1) To determine the maximum tolerated dose (MTD) and the safety profile of KLT in patients with refractory solid tumors; 2) To determine the pharmacokinetics of KLT in patients with refractory solid tumors; and 3) To gather preliminary efficacy data. The method of testing is open-label, sequential cohort, dose-escalation study.

Condition Treatment or Intervention Phase
Solid Tumors Refractory To Standard Therapy
 Drug: Kanglaite Injection (KLT)
Phase I

MedlinePlus related topics:  Cancer;   Cancer Alternative Therapy

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study

Official Title: Phase I Study of KLT in Patients with Solid Tumors Refractory to Standard Therapy

Further Study Details: 

Expected Total Enrollment:  18

Study start: June 2001;  Study completion: June 2002


Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both


  • Patients with histological evidence of malignancy that has become refractory to standard therapy, or for whom effective standard therapy does not exist.
  • Patients with an estimated life-expectancy of at least 3 months
  • Patients with a Karnofsky Performance Score of at least 60%
  • Patients with no history of congestive heart failure (CHF), and normal ejection fraction by echocardiography
  • Patients with adequate renal and hepatic function
  • Patients with adequate bone marrow status

Location Information

      Huntsman Cancer Institue, Salt Lake City,  Utah,  84112,  United States

Study chairs or principal investigators

Richard H Wheeler, M.D.,  Principal Investigator,  Huntsman Cancer Institute   

More Information

Study ID Numbers:  KN-001-01
Record last reviewed:  March 2001
Last Updated:  October 26, 2004
Record first received:  February 20, 2002 Identifier:  NCT00031031
Health Authority: United States: Food and Drug Administration processed this record on 2005-04-08

Cache Date: April 9, 2005